412 related articles for article (PubMed ID: 30011918)
41. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
42. Low cholesterol syndrome and drug development.
Handhle A; Viljoen A; Ramachandran R; Wierzbicki AS
Curr Opin Cardiol; 2020 Jul; 35(4):423-427. PubMed ID: 32452920
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
Mohamed F; Botha TC; Raal FJ
Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
[TBL] [Abstract][Full Text] [Related]
44. Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.
Surma S; Romańczyk M; Filipiak KJ
Cardiol J; 2023; 30(1):131-142. PubMed ID: 33470417
[TBL] [Abstract][Full Text] [Related]
45. How ANGPTL3 Inhibition Will Help Our Clinical Practice?
Bini S; Tramontano D; Minicocci I; Di Costanzo A; Tambaro F; D'Erasmo L; Arca M
Curr Atheroscler Rep; 2023 Jan; 25(1):19-29. PubMed ID: 36607583
[TBL] [Abstract][Full Text] [Related]
46. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
47. New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk.
Kersten S
Curr Opin Lipidol; 2019 Jun; 30(3):205-211. PubMed ID: 30893111
[TBL] [Abstract][Full Text] [Related]
48. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
49. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
50. Structure and Function of Angiopoietin-like Protein 3 (ANGPTL3) in Atherosclerosis.
Lu X
Curr Med Chem; 2020; 27(31):5159-5174. PubMed ID: 31223079
[TBL] [Abstract][Full Text] [Related]
51. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
52. Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers.
Wong Chong E; Joncas FH; Seidah NG; Calon F; Diorio C; Gangloff A
BMC Cancer; 2022 Oct; 22(1):1049. PubMed ID: 36203122
[TBL] [Abstract][Full Text] [Related]
53. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction.
Davidson MH
J Clin Lipidol; 2013; 7(3 Suppl):S11-5. PubMed ID: 23642323
[TBL] [Abstract][Full Text] [Related]
54. Cholesterol-Lowering Agents.
Rosenson RS; Hegele RA; Koenig W
Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
[TBL] [Abstract][Full Text] [Related]
55. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
[TBL] [Abstract][Full Text] [Related]
56. Role of PCSK9 in lipid metabolism and atherosclerosis.
Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
[TBL] [Abstract][Full Text] [Related]
57. Evinacumab for the treatment of homozygous familial hypercholesterolemia.
Gao Y; Zhang B; Yang J
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):139-145. PubMed ID: 35220876
[TBL] [Abstract][Full Text] [Related]
58. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS
Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317
[TBL] [Abstract][Full Text] [Related]
59. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
60. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
